Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2010

View Archived Issues

Indian scientists claim new inhibitors of TNF-alpha production

Cornerstone Pharma adds new site for phase I/II CPI-613 trials in cancer

Southern Research Institute discloses novel antiviral agents

MannKind discloses new agents for pulmonary drug delivery

Mallinckrodt discovers new diagnostics for renal disorders

Novavax's influenza VLP vaccine triggers cytotoxic T-cell proliferation and IFN-gamma secretion

Clinical data presented on abciximab vs. eptifibatide in PCI

BPR-0912 exhibits antiobesity effects in vivo

Lundbeck identifies highly selective M1 receptor agonist

Lpath provides update on four drug development programs

Galapagos acquires full rights to GLPG-0634 for arthritis

FDA grants fast track status to ACE-031 in Duchenne's muscular dystrophy

Agennix presents update on talactoferrin in cancer and severe sepsis

GlaxoSmithKline presents new antimycobacterial agents

Elder Pharmaceuticals discovers new glucose-lowering agents

Cell Therapeutics reports on second quarter 2010

Italian scientists identify new EGFR inhibitors

Clavis advances phase II gemcitabine elaidate trial in pancreatic cancer

GenVec and Novartis expand collaboration on hearing loss and balance disorders

Impax Laboratories and Perrigo collaborate on topical drug products

FDA to complete review of lorcaserin NDA in October

Glycotope begins phase I trial of GT-MAb 5.2-GEX in cancer

FDA does not grant orphan drug status to Levulan PDT for SCC prevention

FDA approves update of Isentress label with 96-week data of trials in HIV-1 infection

Sunesis partners for phase III VALOR trial of vosaroxin in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...